(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Terapia génica y Hepatología > Inmunología hepatitis virales > DA - CIMA - Terapia génica y Hepatología - Inmunología hepatitis virales - Artículos de revista >

Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C
Autor(es) : Gavier, B. (B.)
Martinez-Gonzalez, M.A. (Miguel Ángel)
Riezu-Boj, J.I. (José Ignacio)
Lasarte, J.J. (Juan José)
Garcia, N. (Nicolás)
Civeira, M.P. (María Pilar)
Prieto, J. (Jesús)
Palabras clave : Antiviral Agents/therapeutic use
Hepatitis C/therapy
Interferon-alpha/therapeutic use
Viremia/therapy
Fecha incorporación: 1997
Editorial : WB Saunders
Versión del editor: http://www.sciencedirect.com/science/article/pii/S0016508597005325
ISSN: 1528-0012
Cita: Gavier B, Martinez-Gonzalez MA, Riezu-Boj JI, Lasarte JJ, Garcia N, Civeira MP, et al. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 1997 Nov;113(5):1647-1653.
Resumen
BACKGROUND & AIMS: In chronic hepatitis C, interferon alfa induces sustained remission in less than 30% of treated patients. The aim of this study is to analyze viral status early after initiation interferon therapy as a predictor of treatment outcome. METHODS: One hundred eighty-one patients with chronic hepatitis C who had been treated with interferon alfa for 12 months (median follow-up, 49 months) were studied. Viremia and aminotransferase levels at the first and third months of therapy as well as 10 pretreatment variables were assessed as potential independent predictors of sustained response to treatment. RESULTS: Sustained response occurred in 51 patients (28%). At month 1 of treatment, viral persistence accurately predicted nonresponse (predictive value, 95.3; 95% confidence interval, 86.0-98.8; P < 0.0001). Independent predictors of sustained response were undetectable viremia at the first month of therapy (P < 0.001), undetectable viremia at the third month (P < 0.001), younger age (P = 0.006), nonsporadic infection (P = 0.012), and higher pretreatment aspartate aminotransferase levels (P = 0.032). In patients who cleared HCV RNA at month 1 of therapy, the predicted probability of sustained response averaged 70% for those younger than 30 years and diminished by 10% for each decade of age. CONCLUSIONS: Failure to clear HCV RNA at month 1 of treatment is strongly and independently associated with a very low probability of a sustained response to interferon.
Enlace permanente: http://hdl.handle.net/10171/21677
Aparece en las colecciones: DA - Medicina - MPSP -Artículos de revista
DA - CUN - Medicina interna - Artículos de revista
DA - CIMA - Terapia génica y Hepatología - Virología - Artículos de revista
DA - Medicina - Medicina Interna - Artículos de revista
DA - CIMA - Terapia génica y Hepatología - Inmunología hepatitis virales - Artículos de revista

Ficheros en este registro:
Fichero:  Gastroenterol19971131647.pdf
Descripción: 
Tamaño:  286,89 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.